SCHEMBL10212612

SCHEMBL10212612

Cc1cc(C(=O)N[C@@H]2CCCN(C)C2)no1

nearest known ligand 0.63

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
SMYD3 Q9H7B4 2/20 0.53
CHRNB2 P17787 6/20 0.52
CHRNA4 P43681 6/20 0.52
CHRNB4 P30926 4/20 0.51
CHRNA3 P32297 4/20 0.51
HDAC4 P56524 2/20 0.51
HDAC6 Q9UBN7 2/20 0.51
MALT1 Q9UDY8 1/20 0.51
NPC1 O15118 6/20 0.50
RAB9A P51151 6/20 0.50
SMN1; SMN2 Q16637 3/20 0.50
TSHR P16473 2/20 0.50
ALDH1A1 P00352 1/20 0.49
DRD4 P21917 1/20 0.48
SLC6A2 P23975 1/20 0.48
KCNH2 Q12809 1/20 0.48
MEN1 O00255 1/20 0.47
S1PR1 P21453 1/20 0.47
KMT2A Q03164 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL357812 0.92 SMYD3 (0.52) SMYD3CHRNB2CHRNA4CHRNB4CHRNA3
SCHEMBL9374778 0.84 NPC1 (0.50) SMYD3NPC1RAB9ASMN1; SMN2TSHR
SCHEMBL10211624 0.82 EPHX2 (0.51) HDAC4HDAC6NPC1RAB9ASMN1; SMN2
SCHEMBL22883817 0.82 NPC1 (0.71) NPC1RAB9ASMN1; SMN2TSHRALDH1A1
SCHEMBL9911611 0.80 NPC1 (0.59) SMYD3NPC1RAB9ASMN1; SMN2TSHR
SCHEMBL10210725 0.78 CHRNB2 (0.50) CHRNB2CHRNA4CHRNB4CHRNA3HDAC4
SCHEMBL23507363 0.77 SMYD3 (0.71) SMYD3NPC1RAB9A
SCHEMBL19306739 0.77 SMYD3 (0.71) SMYD3NPC1RAB9A
SCHEMBL23507338 0.77 SMYD3 (0.71) SMYD3NPC1RAB9A
SCHEMBL10211623 0.76 TAS1R3 (0.50) CHRNB2CHRNA4CHRNB4CHRNA3HDAC4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120082702-A1 NICOTINAMIDE COMPOUNDS USEFUL AS KINASE MODULATORS BRISTOL-MEYERS SQUIBB COMPANY 2012-04-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120082702-A1 NICOTINAMIDE COMPOUNDS USEFUL AS KINASE MODULATORS NADK, BTK, NAMPT SMYD3 4250/4885CHRNB2 2261/4885CHRNA4 2418/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.